4
|
Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre-Sancho JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ, Blanco R. Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. J Rheumatol 2021; 48:1552-1558. [PMID: 33795330 DOI: 10.3899/jrheum.201204] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/12/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Tofacitinib (TOF) is the first Janus kinase ( JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-α in randomized controlled trials (RCTs). Our aim was to assess efficacy and safety of TOF in clinical practice. METHODS This was an observational, open-label multicenter study of PsA patients treated with TOF due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, corticosteroid dose-sparing effect, retention rate, and safety. A comparative study of clinical features between our cohort of patients and those from the OPAL Beyond trial was performed. RESULTS There were 87 patients (28 women/59 men), with a mean age of 52.8 ± 11.4 years. All patients were refractory to biologic disease-modifying antirheumatic drugs (DMARDs) and/or to conventional synthetic DMARDs plus apremilast. TOF was started at 5 mg twice daily after a mean follow-up of 12.3 ± 9.3 years from PsA diagnosis. At first month, Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) decreased from median 4.8 (IQR 4.1-5.4) to 3.7 (IQR 2.8-4.7, P < 0.01), Disease Activity Index for Psoriatic Arthritis from median 28 (IQR 18.4-34.1) to 15.5 (IQR 10.1-25.7, P < 0.01), and C-reactive protein from median 1.9 (IQR 0.3-5.0) to 0.5 (IQR 0.1-2.2) mg/dL (P < 0.01). Also, TOF led to a significant reduction in prednisone dose. Mild adverse effects were reported in 21 patients (24.13%), mainly gastrointestinal symptoms. TOF retention rate at Month 6 was 77% (95% CI 65.2-86.3). Patients in clinical practice were older with longer disease duration and received biologic agents more commonly than those in the OPAL Beyond trial. CONCLUSION Data from clinical practice confirm that TOF seems to be effective, rapid, and relatively safe in refractory PsA despite clinical differences with patients in RCTs.
Collapse
Affiliation(s)
- Eva Galíndez-Agirregoikoa
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Diana Prieto-Peña
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - José Luis Martín-Varillas
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Beatriz Joven
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Olga Rusinovich
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Rafael B Melero-González
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Francisco Ortiz-Sanjuan
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Raquel Almodóvar
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Juan José Alegre-Sancho
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Ángels Martínez
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Agustí Sellas-Fernández
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Lara Méndez
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Rosario García-Vicuña
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Belén Atienza-Mateo
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Iñigo Gorostiza
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | - Miguel Ángel González-Gay
- E. Galíndez-Agirregoikoa, MD, Rheumatology Department, Hospital Universitario de Basurto, Bilbao; D. Prieto-Peña, MD, B. Atienza-Mateo, MD, R. Blanco, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Santander; J.L. Martín-Varillas, MD, Rheumatology Department, Hospital de Sierrallana, Torrelavega; B. Joven, MD, Rheumatology Department, Hospital Universitario 12 de Octubre, Madrid; O. Rusinovich, MD, Rheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid; R.B. Melero-González, MD, Rheumatology Department, Complexo Hospitalario Universitario de Vigo, Vigo; F. Ortiz-Sanjuan, MD, PhD, Rheumatology Department, Hospital Universitario Politécnico La Fé, Valencia; R. Almodóvar, MD, Rheumatology Department, Fundación Alcorcón, Madrid; J.J. Alegre-Sancho, MD, Á. Martínez, MD, Rheumatology Department, Hospital Universitario Doctor Peset, Valencia; A. Sellas-Fernández, MD, Rheumatology Department, Hospital Universitari Arnau de Vilanova-Lleida, Lleida; L. Méndez, MD, Rheumatology Department, Hospital Virgen del Rocío, Sevilla; R. García-Vicuña, MD, PhD, Rheumatology Department, Hospital de la Princesa, IIS-Princesa, Cátedra UAM-Roche (EPID-Future), Universidad Autónoma de Madrid, Madrid; I. Gorostiza, MD, Research Group, Hospital Universitario de Basurto, Bilbao; M.Á. González-Gay, MD, PhD, Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, and University of Cantabria, School of Medicine, Santander, Spain, and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. E. Galíndez-Agirregoikoa and D. Prieto-Peña share first authorship. EGA has received research support from Roche, AbbVie, Lilly, Pfizer, MSD, Amgen, BMS, Janssen, and UCB Pharma. DPP has received research support from Roche, AbbVie, Lilly, Pfizer, Sanofi, and UCB Pharma. JLMV has received grants/research supports from AbbVie, Pfizer, Janssen, and Celgene. RBMG has received research support from Roche, AstraZeneca, Sanofi Aventis, BMS, AbbVie, Lilly, Faes, Italfarmaco, Gebro, Esteve, UCB, Novartis, Janssen-Cilag. RA has received research support from AbbVie, Celgene, Gebro, Janssen, Lilly, MSD, Novartis, Pfizer, and UCB. RGV reports grants, personal fees, and nonfinancial support from AbbVie, BMS, Lilly, Novartis, MSD, Pfizer, Sandoz, and Sanofi; personal fees from Biogen, Celltrion, and Mylan; grants from Roche; and grants and personal fees from Janssen, outside the submitted work. BAM is a recipient of a "López- Albo" Post-Residency Programme funded by Servicio Cantabro de Salud, and has received grants/research supports from Kern Pharma, AbbVie, Pfizer, Celgene, and GSK. MAGG has received grants/research supports from AbbVie, MSD, and Roche, and had consultation fees/participation in company-sponsored speakers bureaus from Pfizer, Roche, Sanofi, and Janssen. RB has received grants/ research supports from AbbVie, MSD, and Roche, and had consultation fees/ participation in company-sponsored speakers bureaus from AbbVie, Lilly, Pfizer, Roche, BMS, Janssen, UCB Pharma, and MSD. The remaining authors declared no financial disclosures relevant to this article. Address correspondence to Dr. R. Blanco or Prof. M.A. González-Gay, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/n., ES-39008, Santander, Spain. , . Accepted for publication March 12, 2021
| | | | | |
Collapse
|